The Good, the Bad and the Ugly of pharma stocks

Bilaal Mohamed reveals his best and worst picks from the pharmaceuticals sector.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pharmaceuticals are popular picks for investors but the quality of the investments on offer varies widely.

The Good…

The UK’s largest pharmaceuticals company GlaxoSmithKline (LSE: GSK) saw its shares climb to three-year highs following the EU referendum as investors fled to defensive stocks and overseas earners. Fortunately the FTSE 100 drugs giant fell into both camps and benefitted handsomely as a result. On the flipside, an inflated share price can sometimes have a detrimental effect on the dividend yield for would-be investors, but with the strong prospect of another hike to the shareholder payout this year, Glaxo can still offer a prospective yield of around 5%.

The Brentford-based firm updated the market with an encouraging set of third quarter results last week as it reported higher sales and profits for the period, helped of course by the weaker pound. Pre-tax profits rose to £1.27bn from £867m for the three months to the end of September, on higher revenues of £7.54bn compared to £ £6.13bn for the same period in 2015. Glaxo remains a core holding for many UK portfolios and continues to offer strong attractions for its defensive quality, growing dividends and its overseas earnings.

The Bad…?

Glaxo’s London-listed rival and fellow pharmaceuticals giant AstraZeneca (LSE: AZN) has also benefitted from the UK’s decision to leave the comfort of the European Union, with its share price peaking at record highs above £52 in August. But personally I think the shares’ outperformance masks the drugmaker’s gloomy outlook, as it’s no secret that the Anglo-Swedish firm has struggled with falling revenues and shrinking profits as a result of patent expiries and generic competition on some of its most important drugs.

In its most recent trading update, Astra reported a disappointing set of results for the first half of its financial year. Operating profits were down 28% to $1.3bn, with revenues slipping to $11.7bn as a result of declining product sales, in particular its cholesterol-busting drug Crestor in the US. Unfortunately, the outlook still isn’t great with City analysts anticipating further earnings declines over the next couple of years. Although the dividend remains strong for existing shareholders at 4%, new investors might find Glaxo’s healthier outlook more appealing.

…and the Ugly

Speciality pharmaceuticals business Indivior (LSE: INDV) hasn’t been trading on the London Stock Exchange for very long but has already found itself in a bit of a hot water with the US authorities. In July the Slough-based firm revealed that the Federal Trade Commission was seeking court action over the company’s addiction-control drug Suboxone. It had investigated whether Indivior and its predecessor, Reckitt Benckiser US, had filed a citizen petition with the Food and Drug Administration and negotiated with competing manufacturers to maintain its monopoly.

As if that wasn’t enough to worry about, the Slough-based FTSE 250 firm announced more recently that it was now facing a lawsuit from 35 US states and the District of Columbia alleging violations of state and federal antitrust and consumer protection laws. Indivior has since rebuffed the allegations but nevertheless things could turn ugly. The outlook remains uncertain and I would stay away for now.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Bilaal Mohamed has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

Forget Lloyds’ cheap share price! I’d rather consider this FTSE 100 bargain share

Lloyds' share price might appear too cheap to miss at first glance. But this FTSE-listed share could be a better…

Read more »

Market Movers

Down 6% today, is the BT share price gearing up for a larger fall?

Jon Smith points out why the BT share price has tumbled today, but flags up why the reasoning behind the…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

This FTSE 100 stock is down 25% from its 52-week high. Should I buy?

Analysts think the price-to-earnings ratio of this FTSE 100 stock could fall by half in the next two years if…

Read more »

Investing Articles

£10,000 invested in Nvidia stock just two weeks ago is already worth…

Nvidia stock's been making big losses and big gains so far in 2025, at least on paper. But long-term valuation…

Read more »

Stack of British pound coins falling on list of share prices
Investing Articles

Here’s why Lloyds shares have dipped sharply

Lloyds shares got a boost recently when the Treasury petitoned the Supreme Court to go easy on the car loan…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

A £10,000 investment in BAE Systems shares 5 years ago is now worth…

BAE Systems' shares have lifted off since the start of the decade. But can the FTSE 100 defence giant continue…

Read more »

Dividend Shares

£8,000 invested in high-yield dividend stocks could make this amount of passive income

Jon Smith explains how dividend shares with yields in excess of 8% can be used carefully in order to build…

Read more »

Investing Articles

£5,000 invested in Tesco shares 2 years ago is now worth…

Over the last two years, Tesco shares have provided investors with gains of around 30% per year when dividends are…

Read more »